Investigational Drug Information for TT-00420
✉ Email this page to a colleague
What is the drug development status for TT-00420?
TT-00420 is an investigational drug.
There have been 6 clinical trials for TT-00420.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 17th 2023.
The most common disease conditions in clinical trials are Cholangiocarcinoma, Breast Neoplasms, and Triple Negative Breast Neoplasms. The leading clinical trial sponsors are TransThera Sciences (Nanjing), Inc., TransThera Biosciences Co., Ltd, and [disabled in preview].
Summary for TT-00420
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 4 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2023-11-17) |
| Vendors | 11 |
Recent Clinical Trials for TT-00420
| Title | Sponsor | Phase |
|---|---|---|
| Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor | TransThera Sciences (Nanjing), Inc. | Phase 2 |
| Study to Evaluate the Efficacy and Safety of TT-00420 as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | TransThera Sciences (Nanjing), Inc. | Phase 1/Phase 2 |
| Study to Evaluate the Efficacy and Safety of TT-00420 in Cholangiocarcinoma | TransThera Biosciences Co., Ltd | Phase 2 |
Clinical Trial Summary for TT-00420
Top disease conditions for TT-00420
Top clinical trial sponsors for TT-00420
US Patents for TT-00420
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
